After achieving the ‘best results in its history’ in FY 15 (although slightly short of our more robust growth expectations), Faes Farma reported another strong quarter in Q1 16, with revenue growth of c.11% yoy to c.€57m (c.8% growth in Q1 15), primarily driven by Bilastine and improved traction in the mature drug portfolio. However, following consistent double-digit growth in the past few quarters, animal nutrition had a relatively soft quarter – Ingaso Iberia and Inte
26 Jul 2016
Firing on all cylinders
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Firing on all cylinders
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
26 Jul 2016 -
Author:
Jyoti Prakash -
Pages:
3
After achieving the ‘best results in its history’ in FY 15 (although slightly short of our more robust growth expectations), Faes Farma reported another strong quarter in Q1 16, with revenue growth of c.11% yoy to c.€57m (c.8% growth in Q1 15), primarily driven by Bilastine and improved traction in the mature drug portfolio. However, following consistent double-digit growth in the past few quarters, animal nutrition had a relatively soft quarter – Ingaso Iberia and Inte